newsfilter
← Latest News
ACCESS Newswire·

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis submitted to U.S. FDA in JulyANTHEM Phase 2b trial data of icotrokinra in